Literature DB >> 24776976

Prostate cancer: enzalutamide impresses in European studies.

Sarah Payton.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24776976     DOI： 10.1038/nrurol.2014.98

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  1 in total

1.  Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study.

Authors:  Bertrand Tombal; Michael Borre; Per Rathenborg; Patrick Werbrouck; Hendrik Van Poppel; Axel Heidenreich; Peter Iversen; Johan Braeckman; Jiri Heracek; Edwina Baskin-Bey; Taoufik Ouatas; Frank Perabo; De Phung; Mohammad Hirmand; Matthew R Smith
Journal:  Lancet Oncol       Date:  2014-04-14       Impact factor: 41.316
  1 in total
  1 in total

1.  Prostate cancer: enzalutamide PREVAILs.

Authors:  Sarah Payton
Journal:  Nat Rev Urol       Date:  2014-06-17       Impact factor: 14.432
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.